Study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19
New research by Kaleido Biosciences, Inc., and UMass Medical School investigators John P. Haran, MD, Ph.D., and Beth McCormick, Ph.D., shows that the company's microbiome metabolic therapy candidate produced positive results ...